See more : Tarapur Transformers Limited (TARAPUR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPid Ltd. (PYPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPid Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- E for L Aim Public Company Limited (EFORL.BK) Income Statement Analysis – Financial Results
- NuTech Energy Resources, Inc. (NERG) Income Statement Analysis – Financial Results
- Oriental Carbon & Chemicals Limited (OCCL.NS) Income Statement Analysis – Financial Results
- Shanghai Feilo Acoustics Co.,Ltd (600651.SS) Income Statement Analysis – Financial Results
- Clean Seas Seafood Limited (CTUNF) Income Statement Analysis – Financial Results
PolyPid Ltd. (PYPD)
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 0.00 | 0.00 |
| Gross Profit | -1.82M | -1.72M | -1.12M | -1.01M | -947.00K | -411.00K | -205.00K | -127.00K | -108.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.15M | 27.99M | 30.42M | 16.95M | 14.08M | 12.55M | 9.74M | 7.71M | 5.63M | 2.64M | 1.38M |
| General & Administrative | 0.00 | 8.01M | 9.48M | 7.70M | 4.48M | 5.27M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Selling & Marketing | 0.00 | 2.89M | 2.97M | 1.61M | 887.00K | 549.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.90M | 10.90M | 12.45M | 9.32M | 4.48M | 5.81M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.05M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Cost & Expenses | 22.87M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Interest Income | 548.00K | 267.00K | 468.00K | 474.00K | 60.00K | 126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71M | 1.02M | 0.00 | 17.00K | 15.00K | 42.00K | 40.69M | 1.13M | -1.53M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 71.00K | 60.00K |
| EBITDA | -20.26M | -36.37M | -41.48M | -35.86M | -5.94M | -42.15M | -13.60M | -10.13M | -7.95M | -3.51M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.87M | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M | -13.80M | -10.26M | -11.28M | -3.58M | -1.79M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -929.00K | -540.00K | 544.00K | -10.60M | 11.66M | 24.28M | -40.69M | -1.13M | -1.18M | -305.00K | -3.00K |
| Income Before Tax | -23.80M | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M | -54.49M | -11.39M | -9.75M | -3.88M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.00K | 97.00K | -1.62M | -1.55M | -11.66M | -24.28M | 40.69M | 1.13M | -1.53M | 305.00K | 3.00K |
| Net Income | -23.87M | -39.53M | -40.71M | -35.32M | 4.75M | 5.92M | -54.49M | -11.39M | -8.22M | -3.88M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| EPS Diluted | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| Weighted Avg Shares Out | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
| Weighted Avg Shares Out (Dil) | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
• Recruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery
PolyPid Presents today at The Raymond James Human Health Innovation Conference
Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT
PolyPid to Present at Upcoming Healthcare Investor Conferences
PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team will present at...
PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal Surgery
PolyPid Ltd (NASDAQ: PYPD) has received written responses from the FDA to a Type B meeting request that the company submitted regarding its development plan for its lead candidate, D-PLEX100. The FDA indicated that PolyPid's proposal for a single Phase 3 pivotal study...
PolyPid's (PYPD) CEO Amir Weisberg on Q1 2021 Results - Earnings Call Transcript
PolyPid's (PYPD) CEO Amir Weisberg on Q1 2021 Results - Earnings Call Transcript
PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update
• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery
PolyPid to Participate in Upcoming Investor Conferences
PETAH TIKVA, Israel, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond James 42nd Annual Institutional Investors...
PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of Post-Abdominal Surgery Incisional Infections
Top-line Data Anticipated by Year End 2021
PolyPid's (PYPD) Management on Q4 2020 Results - Earnings Call Transcript
PolyPid's (PYPD) Management on Q4 2020 Results - Earnings Call Transcript
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
PETAH TIKVA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its fourth quarter and...
Source: https://incomestatements.info
Category: Stock Reports